DSpace Repository

Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2

Show simple item record

dc.contributor.author Weecharangsan W.
dc.contributor.author Lee R.J.
dc.date.accessioned 2021-04-05T03:34:01Z
dc.date.available 2021-04-05T03:34:01Z
dc.date.issued 2012
dc.identifier.issn 10717544
dc.identifier.other 2-s2.0-84866256041
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/14294
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866256041&doi=10.3109%2f10717544.2012.714810&partnerID=40&md5=49c52723b72986b90604e875f73414ff
dc.description.abstract Previous study has shown human serum albumin (HSA) coated liposomes can deliver bcl-2 antisense oligodeoxyribonucleotide (ODN) into KB carcinoma cells, and decrease bcl-2 mRNA and protein expression level. In the current study, cell growth inhibition and chemosensitization of KB cells were evaluated. Liposomes composed of dimethyldioctadecyl ammonium bromide/egg phosphatidylcholine/ α-tocopheryl polyethylene glycol 1000 succinate (58:40:2 molar ratio) complexed with bcl-2 antisense ODN and coated with HSA were examined for cell growth inhibition and sensitization to a commonly used chemotherapeutic drug, doxorubicin. HSA-coated liposomeODN complexes effectively inhibited cell growth in the range of ODN concentration of 0.457.2 M. Upon posttreatment with doxorubicin, the cytotoxicity was further significantly increased compared to the ODN complexes alone. The cytotoxicity was dependent on antisense ODN concentration, incubation time and doxorubicin concentration, and relatively independent on HSA concentration. This study suggests that HSA-coated liposomes are effective delivery vehicles for antisense ODN with potential therapeutic application and can be effectively combined with doxorubicin. © 2012 Informa Healthcare USA, Inc.
dc.subject alpha tocopheryl polyethylene glycol 1000 succinate
dc.subject antisense oligodeoxynucleotide
dc.subject dimethyldioctadecyl ammonium bromide
dc.subject doxorubicin
dc.subject egg phosphatidylcholine
dc.subject human serum albumin
dc.subject liposome
dc.subject messenger RNA
dc.subject protein bcl 2
dc.subject unclassified drug
dc.subject article
dc.subject carcinoma cell
dc.subject cell growth
dc.subject cell strain KB
dc.subject chemosensitization
dc.subject concentration response
dc.subject controlled study
dc.subject cytotoxicity
dc.subject drug coating
dc.subject drug delivery system
dc.subject genetic transfection
dc.subject growth inhibition
dc.subject human
dc.subject human cell
dc.subject incubation time
dc.subject mouth carcinoma
dc.subject priority journal
dc.subject protein expression
dc.subject Antibiotics, Antineoplastic
dc.subject Cell Growth Processes
dc.subject Cell Line, Tumor
dc.subject Dose-Response Relationship, Drug
dc.subject Doxorubicin
dc.subject Gene Expression Regulation, Neoplastic
dc.subject Humans
dc.subject KB Cells
dc.subject Lipids
dc.subject Liposomes
dc.subject Mouth Neoplasms
dc.subject Oligodeoxyribonucleotides, Antisense
dc.subject Proto-Oncogene Proteins c-bcl-2
dc.subject RNA, Messenger
dc.subject Serum Albumin
dc.subject Time Factors
dc.title Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2
dc.type Article
dc.rights.holder Scopus
dc.identifier.bibliograpycitation Drug Delivery. Vol 19, No.6 (2012), p.292-297
dc.identifier.doi 10.3109/10717544.2012.714810


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics